ClinicalTrials.gg
TerminatedNCT03127098Updated Aug 6, 2024Results posted

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

A Phase 1/2 interventional study of ETBX-011 and ALT-803 in Thyroid Cancer, Colon Cancer and Ovarian Cancer, sponsored by NantCell, Inc.. Terminated at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by NantCell, Inc. (part of ImmunityBio, Inc.) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated before any dose escalation occurred in order to pursue other studies designed to more extensively evaluate the combination of ETBX-011 and N-803 along with other immunotherapy agents.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Thyroid Neoplasms with a site in United States — 54 open to participants now, 89 under way, 3 of them phase 3. Thyroid Neoplasms · United States.

Enrollment
225th of 231
3 · median 35
Started
2017
with 19 others
Phase 1/2
20 of 283
4 open now
Registered
162nd of 283
by date

Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 225th largest by enrollment of the 231 interventional ones that give a count, is one of 20 that started in 2017, is one of 20 in phase 1/2, and was the 162nd registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

54 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Thyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred after standard-of-care treatment.

Read the detailed description

The trial will consist of a phase 1b study with ETBX-011 as a fixed dose with a dose escalation of ALT-803 unless de-escalation is required. The proposed phase 2 expansion study will give additional safety data for the MTD as well as preliminary efficacy data. Subjects will receive treatments unless they experience progressive disease, dose-limiting toxicities (DLT), withdraw consent, or if the investigator determines it is no longer in their best medical interest to continue treatment.

03

Conditions studied

  • Thyroid Cancer
  • Colon Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer

Keywords

  • locally advanced or metastatic
  • carcinoembryonic antigen (CEA)-expressing
  • CEA
  • carcinoembryonic antigen
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 21 years.
  2. Subjects with a confirmed diagnosis of locally advanced or who were previously treated with at least one method of standard therapy known to have a possible survival benefit or refused such therapy.
  3. The tumor must express CEA or must be known to be universally CEA positive (ie, colon and rectal cancer).
  4. Must have a recent FFPE tumor specimen.
  5. Subjects who have received prior CEA-targeted immunotherapy (eg, vaccine or antibody) are eligible for this trial if this treatment was discontinued at least 3 months prior to enrollment.
  6. Resolution of all toxic side effects of prior chemotherapy, radiotherapy, or surgical procedures to grade ≤ 1.
  7. Ability to understand and provide signed that fulfills Institutional Review Board (IRB)'s guidelines.
  8. performance status of 0 or 1.
  9. Subjects who are taking medications that do not have a known history of are eligible for this trial.
  10. Adequate hematologic function at screening, as follows:
  11. WBC count ≥ 3000/microliter.
  12. ≥ 9 g/dL (may not transfuse or use erythropoietin to achieve this level).
  13. ≥ 75,000/microliter.
  14. Prothrombin (PT)- (INR) \< 1.5.
  15. Partial thromboplastin time (PTT) \< 1.5 × (ULN).
  16. Adequate renal and hepatic function at screening, as follows:
  17. Serum creatinine \< 2.0 mg/dL.
  18. \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL).
  19. (ALT) ≤ 2.5 × ULN.
  20. Aspartate aminotransferase (AST) ≤ 2.5 × ULN.
  21. Female subjects of and women \< 12 months since the onset of menopause must agree to use acceptable methods for the duration of the study and for 7 months following the last injection of study medication. Male subjects must be surgically sterile or must agree to use a condom and acceptable contraceptive method with their partner.
  22. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participation in an drug or device study within 30 days of screening for this study.
  2. Pregnant and nursing women.
  3. Subjects with ongoing everolimus or other cancer therapy that interferes with the induction of immune responses.
  4. Subjects with concurrent cytotoxic chemotherapy or radiation therapy. There must be at least one (1) month between any other prior chemotherapy (or radiotherapy) and study treatment. Any prior CEA-targeted immunotherapy (vaccine) must have been discontinued at least 3 months before initiation of study treatment. Subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study.
  5. Active brain or central nervous system , seizures requiring anticonvulsant treatment, cerebrovascular accident (\< 6 months), or .
  6. Subjects with a history of disease (active or past), such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune-related thyroid disease and vitiligo are permitted.
  7. Subjects with serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, or other illness considered by the Investigator as high risk for investigational drug treatment.
  8. Subjects with a history of heart disease, such as congestive heart failure (class II, III, or IV defined by the functional classification), history of unstable or poorly controlled angina, or history (\< 1 year) of ventricular arrhythmia.
  9. Subjects with a medical or psychological impediment that would impair the ability of the subject to receive therapy per protocol or impact ability to comply with the protocol or protocol-required visits and procedures.
  10. History of except for the following: adequately treated non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other carcinoma that has been in complete remission without treatment for more than 5 years.
  11. Presence of a known active acute or chronic infection, including (HIV, as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by western blot) and and virus (HBV/HCV, as determined by HBsAg and hepatitis C serology).
  12. Subjects on systemic intravenous or oral therapy (or other immunosuppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Subjects must have had at least 6 weeks of discontinuation of any steroid therapy (except that used as premedication for chemotherapy or contrast-enhanced studies) prior to enrollment.
  13. Subjects with known allergy or to any component of the investigational product will be excluded.
  14. Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
  15. Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist®) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX®, Fluzone®) within 28 days or 14 days, respectively, of the first planned dose of ETBX-011 or 803.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ETBX-011 in combination with ALT-803

    A combination of agents were administered to subjects in this dose-escalation study

    Biological: ETBX-011 · Biological: ALT-803

Interventions

  • BiologicalETBX-011

    ETBX-011 immunization was administered by subcutaneous (SC) injection.

    Also known as: Ad5 [E1-, E2b-]-CEA(6D)

  • BiologicalALT-803

    ALT-803 was administered by SC injection.

    Also known as: Super-agonist IL-15, IL-15

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities

    Time frame: 9 weeks

Secondary outcomes

  1. Duration of Response

    The duration of overall response was measured from the time measurement criteria are met for CR or PR (whichever was first recorded) until the first date that recurrent or PD was objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started).

    Time frame: Up to 11 weeks

  2. Progression Free Survival

    PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurred first. Subjects who did not have disease progression or did not die at the end of follow up were to be censored at the last known date the subject was progression free.

    Time frame: Up to 11 weeks

  3. Overall Survival

    OS was evaluated by dose cohort and overall using the Kaplan-Meier method. OS was defined as the time from the date of first treatment to the date of death from any cause. Subjects who were alive at the end of follow up were to be censored at the last known date alive.

    Time frame: Up to 6 months

07

Results

Posted Aug 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneETBX-011 in Combination With ALT-803
Started3
Completed3
Not completed0

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities
Time frame:
9 weeks
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities
ParticipantsETBX-011 in Combination With ALT-803
Number of Participants With Dose-Limiting Toxicities1
SecondaryDuration of Response

The duration of overall response was measured from the time measurement criteria are met for CR or PR (whichever was first recorded) until the first date that recurrent or PD was objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started).

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

SecondaryProgression Free Survival

PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurred first. Subjects who did not have disease progression or did not die at the end of follow up were to be censored at the last known date the subject was progression free.

Time frame:
Up to 11 weeks
Reported as:
Count of participants · Participants
Progression Free Survival
ParticipantsETBX-011 in Combination With ALT-803
Progression Free Survival3
SecondaryOverall Survival

OS was evaluated by dose cohort and overall using the Kaplan-Meier method. OS was defined as the time from the date of first treatment to the date of death from any cause. Subjects who were alive at the end of follow up were to be censored at the last known date alive.

Time frame:
Up to 6 months
Reported as:
Number · Months
Overall Survival
MonthsETBX-011 in Combination With ALT-803
Overall SurvivalNA

Adverse events

Collected over Non-serious AEs were to be followed for 30 days after subject's last dose of ETBX-011+ALT-803, up to 13 weeks . Non-serious grade 3/4 AEs were to be followed until resolution or stabilization, up to 13 weeks. All SAEs that did not resolve upon discontinuation of the subject's participation in the study were to be followed until recovered, recovered w/ sequelae, lost to follow-up, otherwise, up to 13 weeks. All-Cause Mortality was assessed through study completion, up to 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETBX-011 in Combination With ALT-8030/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventETBX-011 in Combination With ALT-803
Injection site erythemaGeneral disorders3/3
Injection site oedemaGeneral disorders3/3
Injection site painGeneral disorders3/3
Injection site pruritusGeneral disorders3/3
ChillsGeneral disorders2/3
FatigueGeneral disorders2/3
Influenza like illnessGeneral disorders2/3
Lymph node painBlood and lymphatic system disorders1/3
Visual impairmentEye disorders1/3
Abdominal painGastrointestinal disorders1/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)ETBX-011 in Combination With ALT-803
Mean63.7 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)ETBX-011 in Combination With ALT-803
Female1
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ETBX-011 in Combination With ALT-803
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
Subjects with previously treated locally advanced or metastatic CEA-expressing cancer
Subjects with previously treated locally advanced or metastatic CEA-expressing cancer(Participants)ETBX-011 in Combination With ALT-803
Count of participants3
08

Study locations

1 site
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Dec 2017, 5 months.

Results were first posted in Aug 2024, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2017
First posted
Apr 25, 2017
StartActual
Jun 26, 2017
Primary completionActual
Dec 7, 2017
CompletionActual
Dec 7, 2017
Results first posted
Aug 6, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03127098
Lead sponsor
NantCell, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Jun 26, 2017
Primary completion
Dec 7, 2017
Completion
Dec 7, 2017
Results posted
Aug 6, 2024
Last update
Aug 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ETBX-011 · Nogapendekin alfa inbakicept

Start the discussion